Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA grew its holdings in shares of Annexon, Inc. (NASDAQ:ANNX) by 9.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,160,886 shares of the company’s stock after purchasing an additional 96,085 shares during the period. Massachusetts Financial Services Co. MA owned approximately 1.10% of Annexon worth $6,872,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of ANNX. Comerica Bank purchased a new stake in Annexon during the first quarter worth about $72,000. Sandia Investment Management LP acquired a new stake in shares of Annexon in the 2nd quarter worth approximately $49,000. Victory Capital Management Inc. purchased a new position in Annexon in the 2nd quarter valued at approximately $51,000. Principal Financial Group Inc. acquired a new position in Annexon during the second quarter worth $56,000. Finally, ProShare Advisors LLC purchased a new stake in Annexon during the first quarter worth $87,000.

Insider Buying and Selling

In related news, EVP Ted Yednock sold 5,408 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $7.41, for a total value of $40,073.28. Following the completion of the sale, the executive vice president now directly owns 71,365 shares in the company, valued at approximately $528,814.65. The trade was a 7.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 20,908 shares of company stock worth $135,768. 12.67% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ANNX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price target on shares of Annexon in a research note on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Annexon in a research report on Friday, November 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Annexon has an average rating of “Buy” and a consensus price target of $15.80.

Annexon Stock Performance

Shares of ANNX opened at $5.29 on Wednesday. Annexon, Inc. has a 1 year low of $2.27 and a 1 year high of $8.40. The company has a market capitalization of $563.86 million, a price-to-earnings ratio of -5.04 and a beta of 1.23. The company’s 50 day simple moving average is $6.75 and its 200 day simple moving average is $5.95.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.